caa a22 4500 606242708 CHVBK 20210128101320.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s12602-014-9181-3 doi (NATIONALLICENCE)springer-10.1007/s12602-014-9181-3 Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study [Elektronische Daten] [Caterina Holz, Andreas Busjahn, Heidrun Mehling, Stefanie Arya, Mewes Boettner, Hajar Habibi, Christine Lang] Reducing the amount of Helicobacter pylori in the stomach by selective bacterial-bacterial cell interaction was sought as an effective and novel method for combating the stomach pathogen. Lactobacillus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lactobacillus species. Applying a stringent screening procedure, the strain DSM17648 was identified as selective binder to H. pylori cells under in vivo gastric conditions. The strain DSM17648 co-aggregates the pathogen in vivo and in vitro. The specific co-aggregation occurs between Lact. reuteri DSM17648 and different H. pylori strains and serotypes, as well as H. heilmannii, but not with Campylobacter jejuni or other commensal oral and intestinal bacteria. Lact. reuteri DSM17648 was shown in a proof-of-concept single-blinded, randomized, placebo-controlled pilot study to significantly reduce the load of H. pylori in healthy yet infected adults. Reducing the amount of H. pylori in the stomach by selective bacterial-bacterial cell interaction might be an effective and novel method for combating the stomach pathogen. Lact. reuteri DSM17648 might prove useful as an adhesion blocker in antibiotic-free H. pylori therapies. The Author(s), 2014 Helicobacter pylori nationallicence Lactobacillus reuteri nationallicence Selective binding nationallicence Co-aggregation nationallicence Urea breath test nationallicence Antibiotic-free therapy nationallicence Holz Caterina ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut Busjahn Andreas HealthTwiST GmbH, Lindenberger Weg 80, 13125, Berlin, Germany aut Mehling Heidrun Experimental and Clinical Research Center, Charité Campus Berlin-Buch (CCB), Lindenberger Weg 80, 13125, Berlin, Germany aut Arya Stefanie ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut Boettner Mewes ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut Habibi Hajar ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut Lang Christine ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut Probiotics and Antimicrobial Proteins Springer US; http://www.springer-ny.com 7/2(2015-06-01), 91-100 1867-1306 7:2<91 2015 7 12602 https://doi.org/10.1007/s12602-014-9181-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s12602-014-9181-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Holz Caterina ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut NATIONALLICENCE 700 1- Busjahn Andreas HealthTwiST GmbH, Lindenberger Weg 80, 13125, Berlin, Germany aut NATIONALLICENCE 700 1- Mehling Heidrun Experimental and Clinical Research Center, Charité Campus Berlin-Buch (CCB), Lindenberger Weg 80, 13125, Berlin, Germany aut NATIONALLICENCE 700 1- Arya Stefanie ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut NATIONALLICENCE 700 1- Boettner Mewes ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut NATIONALLICENCE 700 1- Habibi Hajar ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut NATIONALLICENCE 700 1- Lang Christine ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany aut NATIONALLICENCE 773 0- Probiotics and Antimicrobial Proteins Springer US; http://www.springer-ny.com 7/2(2015-06-01), 91-100 1867-1306 7:2<91 2015 7 12602